Imara is a company, dedicated to developing novel therapeutics for people living with sickle cell disease and other hemoglobinopathies. The Company offers IMR-687, an oral, and selective phosphodiesterase 9 (PDE9) inhibitor to treat patients with sickle cell disease by both reducing red blood cell sickling and blockage of blood vessels that are underlying causes of the pathology of sickle cell disease.
|Employees (est.) (Feb 2020)||20|
|Share Price (Mar 2020)||$16||(-1%)|
Net income (FY, 2019)
EBIT (FY, 2019)
Market capitalization (26-Mar-2020)
Closing stock price (26-Mar-2020)
Imara has 174 Twitter Followers. The number of followers has increased 4.8% month over month and increased 17.4% quarter over quarter
When was Imara founded?
Imara was founded in 2015.
Who are Imara key executives?
Imara's key executives are Rahul D. Ballal, Willem H. Scheele and Michael P. Gray.
How many employees does Imara have?
Imara has 20 employees.
Who are Imara competitors?
Competitors of Imara include ReViral, Sosei Heptares and Seres Therapeutics.
Where is Imara headquarters?
Imara headquarters is located at 116 Huntington Ave 6th floor, Boston.
Where are Imara offices?
Imara has an office in Boston.
How many offices does Imara have?
Imara has 1 office.
Receive alerts for 300+ data fields across thousands of companies